ROCKVILLE, Md.--(BUSINESS WIRE)--Rexahn Pharmaceuticals (OTCBB:RXHN) today announced that it has been awarded a grant through the Maryland Industrial Partnerships Program (MIPS). With the grant, researchers at Rexahn and the University of Maryland, Baltimore (UMB) Center for Nanomedicine & Cellular Delivery (CNCD), will jointly pursue the development of water-soluble nano-polymers for targeted delivery of anticancer drugs.
